These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7865289)

  • 1. Phase I/II trials of preventive HIV vaccine candidates. Dose and schedule: summary.
    Gorse GJ
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S141-3. PubMed ID: 7865289
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV vaccines. Viral envelope fails to deliver?
    Bolognesi DP; Matthews TJ
    Nature; 1998 Feb; 391(6668):638-9. PubMed ID: 9490406
    [No Abstract]   [Full Text] [Related]  

  • 3. Policy rebuttal. HIV vaccine trial justified.
    McNeil JG; Johnston MI; Birx DL; Tramont EC
    Science; 2004 Feb; 303(5660):961. PubMed ID: 14963313
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.
    Robinson HL; Weinhold KJ
    J Infect Dis; 2006 Dec; 194(12):1625-7. PubMed ID: 17109331
    [No Abstract]   [Full Text] [Related]  

  • 5. Statistical evaluation of HIV vaccines in early clinical trials.
    Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND
    Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
    Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
    Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.
    Nitayaphan S; Pitisuttithum P; Karnasuta C; Eamsila C; de Souza M; Morgan P; Polonis V; Benenson M; VanCott T; Ratto-Kim S; Kim J; Thapinta D; Garner R; Bussaratid V; Singharaj P; el-Habib R; Gurunathan S; Heyward W; Birx D; McNeil J; Brown AE;
    J Infect Dis; 2004 Aug; 190(4):702-6. PubMed ID: 15272397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Support for the RV144 HIV vaccine trial.
    Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
    DePalma L
    Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
    [No Abstract]   [Full Text] [Related]  

  • 10. [How far away is the first anti-HIV vaccine?].
    Bürk RR
    Fortschr Med; 1994 Mar; 112(7):61-2. PubMed ID: 8175095
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
    Hinkula J
    Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization. Update: search for an AIDS vaccine.
    Bende S; Johnston MI
    AIDS Read; 2000 Sep; 10(9):526-32, 534-8. PubMed ID: 11019448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials.
    Hudgens MG
    Stat Med; 2003 Feb; 22(3):463-79. PubMed ID: 12529875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.
    Johnson DC; McFarland EJ; Muresan P; Fenton T; McNamara J; Read JS; Hawkins E; Bouquin PL; Estep SG; Tomaras GD; Vincent CA; Rathore M; Melvin AJ; Gurunathan S; Lambert J
    J Infect Dis; 2005 Dec; 192(12):2129-33. PubMed ID: 16288378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outstanding questions on HIV vaccine trial.
    Jefferys R; Harrington M
    Science; 2004 Jul; 305(5681):180; author reply 180. PubMed ID: 15247456
    [No Abstract]   [Full Text] [Related]  

  • 17. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thailand's Prime-Boost HIV Vaccine Phase III.
    Trinvuthipong C
    Science; 2004 Feb; 303(5660):954-5. PubMed ID: 14963308
    [No Abstract]   [Full Text] [Related]  

  • 19. Starting from scratch: program development and lessons learned from HIV vaccine trial counseling in Thailand.
    Thapinta D; Jenkins RA
    Contemp Clin Trials; 2007 Jul; 28(4):409-22. PubMed ID: 17196444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.